Files
statdx/docs_md/articles/craniopharyngioma_00e66680-6731-4287-b5a1-3f0b3f09053b.md
2025-10-20 21:15:33 +01:00

32 KiB

title, docid, authors, breadcrumbs, category, documentVersionId, imageCount, lastUpdated, pageDescription, pageKeywords, pageTitle, enhancedTitle, type, references, breadcrumbs
title docid authors breadcrumbs category documentVersionId imageCount lastUpdated pageDescription pageKeywords pageTitle enhancedTitle type references breadcrumbs
Craniopharyngioma 00e66680-6731-4287-b5a1-3f0b3f09053b
key value
8d5254e9-8dda-478b-8f08-bdee97a32c79 Karen L. Salzman, MD, FACR
name slug treeNodeId
Brain brain 6d8829f1-14d7-45af-8675-255189aa526a
name slug treeNodeId
Diagnosis diagnosis 51c00394-446e-4a38-94af-d3b1d14d34e8
name slug treeNodeId
Anatomy-Based Diagnoses anatomy-based-diagnoses 529d3e33-f508-498c-bc70-cf962e81e629
name slug treeNodeId
Sella and Pituitary sella-and-pituitary 9afaeeb6-661c-49be-b55f-5bdc1c98a53e
name slug treeNodeId
Neoplasms neoplasms 87c53ba9-d217-4dc9-be90-15cfe4d7766c
name slug treeNodeId
Craniopharyngioma craniopharyngioma null
Brain fba662fa-55e8-45a2-8081-e59d71a73b51 19 08/10/20 Craniopharyngioma Brain, Diagnosis, Anatomy-Based Diagnoses, Sella and Pituitary, Neoplasms, Craniopharyngioma Craniopharyngioma | STATdx Craniopharyngioma DX true
Brain
Diagnosis
Anatomy-Based Diagnoses
Sella and Pituitary
Neoplasms
Craniopharyngioma

title: "Craniopharyngioma" docid: "00e66680-6731-4287-b5a1-3f0b3f09053b" authors:

  • key: "8d5254e9-8dda-478b-8f08-bdee97a32c79" value: "Karen L. Salzman, MD, FACR" breadcrumbs:
  • name: "Brain" slug: "brain" treeNodeId: "6d8829f1-14d7-45af-8675-255189aa526a"
  • name: "Diagnosis" slug: "diagnosis" treeNodeId: "51c00394-446e-4a38-94af-d3b1d14d34e8"
  • name: "Anatomy-Based Diagnoses" slug: "anatomy-based-diagnoses" treeNodeId: "529d3e33-f508-498c-bc70-cf962e81e629"
  • name: "Sella and Pituitary" slug: "sella-and-pituitary" treeNodeId: "9afaeeb6-661c-49be-b55f-5bdc1c98a53e"
  • name: "Neoplasms" slug: "neoplasms" treeNodeId: "87c53ba9-d217-4dc9-be90-15cfe4d7766c"
  • name: "Craniopharyngioma" slug: "craniopharyngioma" treeNodeId: null category: "Brain" documentVersionId: "fba662fa-55e8-45a2-8081-e59d71a73b51" imageCount: 19 lastUpdated: "08/10/20" pageDescription: "Craniopharyngioma" pageKeywords: "Brain, Diagnosis, Anatomy-Based Diagnoses, Sella and Pituitary, Neoplasms, Craniopharyngioma" pageTitle: "Craniopharyngioma | STATdx" enhancedTitle: "Craniopharyngioma" type: "DX" references: true breadcrumbs:
  • "Brain"
  • "Diagnosis"
  • "Anatomy-Based Diagnoses"
  • "Sella and Pituitary"
  • "Neoplasms"
  • "Craniopharyngioma"

KEY FACTS

  • Terminology

    • Benign, partially cystic sellar region tumor derived from remnants of craniopharyngeal duct/Rathke pouch epithelium
    • 2 types - Adamantinomatous (cystic mass in childhood) - Papillary (solid mass in older adults)
  • Imaging

    • General features - Multilobulated, often large (> 5 cm) - Occasionally giant, multicompartmental
    • CT: Cystic (90%), Ca⁺⁺ (90%), enhancing (90%)
    • MR: Signal varies with cyst contents - Cysts variably hyperintense on T1WI and T2WI - Solid portions enhance heterogeneously; cyst walls enhance strongly - Cyst contents show broad lipid peak (0.9-1.5 ppm) on MR spectroscopy
  • Pathology

    • Most common pediatric intracranial tumor of nonglial origin
    • WHO grade 1
  • Clinical Issues

    • Bimodal age distribution - Peak 5-15 years; adults 45-60 years (commonly papillary)
    • Pediatric patient with morning headache, visual defect, short stature - Endocrine disturbances include growth hormone (GH) deficiency, luteinizing hormone (LH)/follicle-stimulating hormone (FSH) deficiency - Others = hypothyroidism > adrenal failure > diabetes insipidus
    • Surgical resection is primary therapy
    • Surgery, radiation therapy, or cyst aspiration for recurrent tumors

TERMINOLOGY

  • Abbreviations

    • Craniopharyngioma (CP)
  • Synonyms

    • Craniopharyngeal duct tumor, Rathke pouch tumor, adamantinoma
  • Definitions

    • Benign, partially cystic sellar region tumor derived from Rathke pouch epithelium - 2 histologies: Adamantinomatous and papillary

IMAGING

  • General Features

    • Best diagnostic clue

      - CT: Partially Ca⁺⁺ mixed solid/cystic suprasellar mass in child
      - MR: Complex signal intensity suprasellar mass
      
    • Location

      - Surgical division of CPs into 3 groups
              - Sellar
              - Prechiasmatic
              - Retrochiasmatic
      - Imaging locations of CPs (adamantinomatous type)
              - Suprasellar (75%)
              - Suprasellar + intrasellar component (21%)
              - Entirely intrasellar (4%)
              - Often extends into multiple cranial fossae: Anterior (30%), middle (23%), posterior, &/or retroclival (20%)
      - Rare ectopic locations
              - Optic chiasm, 3rd ventricle
              - Other: Nasopharynx, paranasal sinuses, pineal gland, sphenoid (clivus), cerebellopontine angle
      
    • Size

      - Variable; often large at presentation (> 5 cm)
              - Occasionally giant, multicompartmental
      
    • Morphology

      - Multilobulated, multicystic
      
  • CT Findings

    • NECT

      - Adamantinomatous type (90% rule)
              - 90% mixed solid (isodense), cystic (hypodense)
              - 90% calcify
              - 90% enhance (solid = nodule; rim = capsule)
      - Papillary type: Often solid, isodense, rarely calcifies
      
  • MR Findings

    • T1WI

      - Signal varies with cyst contents
              - Short T1 due to high protein content
              - Classic (adamantinomatous type)
                        - Hyperintense cyst + heterogeneous nodule
              - Less common (papillary type)
                        - Isointense solid component
      
    • T2WI

      - Cysts are variably hyperintense
      - Solid component = heterogeneous (iso-/hyperintense, Ca⁺⁺ portions hypointense)
      - Hyperintense signal in brain parenchyma adjacent to tumor may indicate
              - Gliosis, tumor invasion, irritation from leaking cyst fluid
              - Edema from compression of optic chiasm/tracts
              - Hypointense T2* = Ca⁺⁺
      
    • FLAIR

      - Cyst contents typically hyperintense
      
    • DWI

      - Variable depending upon character of cyst fluid
      
    • T1WI C+

      - Solid portions enhance heterogeneously; cyst walls enhance strongly
      
    • MRA

      - Vascular displacement &/or encasement
      
    • MRS

      - Cyst contents show broad lipid spectrum (0.9-1.5 ppm)
      
  • Imaging Recommendations

    • Best imaging tool

      - MR with thin sagittal, coronal sequences
      
    • Protocol advice

      - Pre-/postcontrast T1WI, T2, FLAIR, GRE, DWI, MRS
      

DIFFERENTIAL DIAGNOSIS

  • Rathke Cleft Cyst

    • Noncalcified, less heterogeneous
    • Look for intracystic nodule on T2
    • Does not enhance - Claw sign (enhancing pituitary draped around cyst)
    • Small Rathke cleft cyst (RCC) may be indistinguishable from rare intrasellar CP
    • RCCs express CK8 and CK20 (CPs generally do not)
  • Suprasellar Arachnoid Cyst

    • No Ca⁺⁺, enhancement
  • Hypothalamic/Chiasmatic Astrocytoma

    • Solid or with small cystic/necrotic components
    • Ca⁺⁺ is rare; robust enhancement is common
  • Pituitary Adenoma

    • Rare in prepubescent children
    • Isointense with brain
    • Enhances strongly
    • Can mimic CP when cystic and hemorrhagic
  • Epidermoid/Dermoid Tumors

    • Minimal or no enhancement
  • Thrombosed Aneurysm

    • Contains blood products; use SWI
    • Look for residual patent lumen, phase artifact
  • Germinoma or Mixed Germ Cell Tumor With Cystic Component(s)

    • Cerebrospinal fluid spread is common, Ca⁺⁺ is rare

PATHOLOGY

  • General Features

    • Etiology

      - 2 proposed theories
              - CPs arise from remnants of craniopharyngeal duct and Rathke pouch epithelium
              - CPs arise from squamous epithelial cells in pars tuberalis of adenohypophysis
      
    • Genetics

      - No known genetic susceptibility (rare reports of siblings, parent-child)
      - Small subset of CPs are monoclonal tumors that arise from oncogenes at specific loci
      - Adamantinomatous: *CTNNB1* mutations and aberrant nuclear expression of β-catenin in up to 95% of cases
      - Papillary:*BRAF* V600E mutations in 81-95% of cases
      
  • Staging, Grading, & Classification

    • WHO grade 1
    • MIB-1 labeling index > 7% predicts recurrence
  • Gross Pathologic & Surgical Features

    • Solid tumor with variable cysts
    • Adamantinomatous cysts often contain thick "crankcase oil" fluid
    • Epithelial fronds penetrate adjacent hypothalamus/chiasm
  • Microscopic Features

    • Adamantinomatous (mostly pediatric) - Multistratified squamous epithelium with nuclear palisading - Nodules of "wet" keratin - Dystrophic Ca⁺⁺
    • Papillary (mostly adults) - Sheets of squamous epithelium form pseudopapillae - Villous fibrovascular stroma
    • Malignant transformation, distant metastases rare - May occur with varied histologies, resulting in poor prognosis

CLINICAL ISSUES

  • Presentation

    • Most common signs/symptoms

      - Symptoms vary with location, size of tumor, age of patient
      - Visual disturbances (60-85%)
              - Bitemporal hemianopsia
      
    • Other signs/symptoms

      - Endocrine disturbances (52-87%)
              - Growth hormone (GH) deficiency (75%) > luteinizing hormone (LH)/follicle-stimulating hormone (FSH) deficiency > hypothyroidism > adrenal failure > diabetes insipidus
              - Headaches
              - Cognitive impairment (~ 50%)
      
    • Clinical profile

      - Pediatric patient with morning headache, visual defect, short stature
      
  • Demographics

    • Age

      - Bimodal distribution (peak 5-15 years, with smaller peak 45-60 years)
              - Papillary CP: 40-55 years
      
    • Sex

      - M = F
      
    • Ethnicity

      - More common in Japanese children
      
    • Epidemiology

      - Most common pediatric intracranial tumor of nonglial origin
      - Comprise 1.2-4.6% of all intracranial tumors across all ages
              - 6-11% of all pediatric intracranial tumors
              - Incidence = 0.5-2.5 new cases per 1 million per year
      - ~ 54% of all pediatric sellar/chiasmatic region tumors are CPs
      
  • Natural History & Prognosis

    • Typically slow-growing benign neoplasm
    • Prognosis based upon size, extent of tumor at presentation - < 5 cm, recurrence rate: 20% - > 5 cm, recurrence rate: 83% - Overall 10-year survival: 64-96%
  • Treatment

    • Methods of primary treatment - Radical surgery = gross total resection - Complications = hypothalamic injury, endocrine symptoms, vasa vasorum injury, and pseudoaneurysm - Surgery may occur via craniotomy, transnasal, transorbital, or endoscopic routes - Less invasive surgery = subtotal resection + radiation therapy - Biopsy, cyst drainage, and radiation therapy
    • Treatment for residual or recurrent tumor - Surgery, radiation therapy, or cyst aspiration - Cyst instillation with intracavitary radioisotopes, bleomycin, or other sclerosing agents

DIAGNOSTIC CHECKLIST

  • Consider

    • Preoperative ophthalmologic and endocrine evaluations
  • Image Interpretation Pearls

    • Use NECT to detect Ca⁺⁺ if MR diagnosis is in question
    • Adamantinomatous CP = 90% rule (90% cystic, calcified, enhancing)
    • Papillary CP is typically solid and primarily adult neoplasm

c497473c-5835-4221-bfa1-0d2be04bee73

References

Selected References

  1. Azuma M et al: Usefulness of contrast-enhanced 3D-FLAIR MR imaging for differentiating Rathke cleft cyst from cystic craniopharyngioma. AJNR Am J Neuroradiol. 41(1):106-10, 2020
  2. Fouda MA et al: Sixty years single institutional experience with pediatric craniopharyngioma: between the past and the future. Childs Nerv Syst. 36(2):291-6, 2020
  3. Goldman S et al: Phase II study of peginterferon alpha-2b for patients with unresectable or recurrent craniopharyngiomas: a Pediatric Brain Tumor Consortium report. Neuro Oncol. ePub, 2020
  4. Prince E et al: Transcriptional analyses of adult and pediatric adamantinomatous craniopharyngioma reveals similar expression signatures regarding potential therapeutic targets. Acta Neuropathol Commun. 8(1):68, 2020
  5. Sadashivam S et al: Adult craniopharyngioma: the role of extent of resection in tumor recurrence and long-term functional outcome. Clin Neurol Neurosurg. 192:105711, 2020
  6. Soldozy S et al: Endoscopic endonasal surgery outcomes for pediatric craniopharyngioma: a systematic review. Neurosurg Focus. 48(1):E6, 2020
  7. Drapeau A et al: Pediatric craniopharyngioma. Childs Nerv Syst. 35(11):2133-45, 2019
  8. Madsen PJ et al: Endoscopic endonasal resection versus open surgery for pediatric craniopharyngioma: comparison of outcomes and complications. J Neurosurg Pediatr. 1-10, 2019
  9. Marcus HJ et al: Craniopharyngioma in children: trends from a third consecutive single-center cohort study. J Neurosurg Pediatr. 1-9, 2019
  10. Whelan R et al: Interrater reliability of a method to assess hypothalamic involvement in pediatric adamantinomatous craniopharyngioma. J Neurosurg Pediatr. 1-6, 2019
  11. Buslei et al: Craniopharyngioma. In Louis DN et al: WHO Classification of Tumors of the Central Nervous System. IARC. 324-8, 2016
  12. Greenfield BJ et al: Long-term disease control and toxicity outcomes following surgery and intensity modulated radiation therapy (IMRT) in pediatric craniopharyngioma. Radiother Oncol. 114(2):224-9, 2015
  13. Kim JH et al: BRAF V600E mutation is a useful marker for differentiating Rathke's cleft cyst with squamous metaplasia from papillary craniopharyngioma. J Neurooncol. 123(1):189-91, 2015
  14. Lee HJ et al: Pretreatment diagnosis of suprasellar papillary craniopharyngioma and germ cell tumors of adult patients. AJNR Am J Neuroradiol. 36(3):508-17, 2015
  15. Sterkenburg AS et al: Survival, hypothalamic obesity, and neuropsychological/psychosocial status after childhood-onset craniopharyngioma: newly reported long-term outcomes. Neuro Oncol. 17(7):1029-38, 2015
  16. Lee CC et al: Gamma Knife surgery for craniopharyngioma: report on a 20-year experience. J Neurosurg. 121 Suppl:167-78, 2014
  17. Clark AJ et al: A systematic review of the results of surgery and radiotherapy on tumor control for pediatric craniopharyngioma. Childs Nerv Syst. 29(2):231-8, 2013
  18. Müller HL: Childhood craniopharyngioma. Pituitary. 16(1):56-67, 2013
  19. Chentli F et al: Congenital craniopharyngioma: a case report and literature review. J Pediatr Endocrinol Metab. 25(11-12):1181-3, 2012
  20. Clark AJ et al: Treatment-related morbidity and the management of pediatric craniopharyngioma: a systematic review. J Neurosurg Pediatr. 10(4):293-301, 2012
  21. İnci MF et al: A rare presentation of craniopharyngioma: delayed puberty. BMJ Case Rep. 2012, 2012
  22. Shi Z et al: Transient enlargement of craniopharyngioma after radiation therapy: pattern of magnetic resonance imaging response following radiation. J Neurooncol. 109(2):349-55, 2012
  23. Boongird A et al: Malignant craniopharyngioma; case report and review of the literature. Neuropathology. 29(5):591-6, 2009
  24. Frangou EM et al: Metastatic craniopharyngioma: case report and literature review. Childs Nerv Syst. 25(9):1143-7, 2009
  25. Keil MF et al: Pituitary tumors in childhood: update of diagnosis, treatment and molecular genetics. Expert Rev Neurother. 8(4):563-74, 2008
  26. Garrè ML et al: Craniopharyngioma: modern concepts in pathogenesis and treatment. Curr Opin Pediatr. 19(4):471-9, 2007
  27. Powers CJ et al: Cerebellopontine angle craniopharyngioma: case report and literature review. Pediatr Neurosurg. 43(2):158-63, 2007
  28. Rodriguez FJ et al: The spectrum of malignancy in craniopharyngioma. Am J Surg Pathol. 31(7):1020-8, 2007
  29. Shuman AG et al: Extracranial nasopharyngeal craniopharyngioma: case report. Neurosurgery. 60(4):E780-1; discussion E781, 2007
  30. Aquilina K et al: Primary cerebellopontine angle craniopharyngioma in a patient with gardner syndrome. Case report and review of the literature. J Neurosurg. 105(2):330-3, 2006
  31. Haupt R et al: Epidemiological aspects of craniopharyngioma. J Pediatr Endocrinol Metab. 19 Suppl 1:289-93, 2006
  32. Prabhu VC et al: The pathogenesis of craniopharyngiomas. Childs Nerv Syst. 21(8-9):622-7, 2005
  33. Wang KC et al: Origin of craniopharyngiomas: implication on the growth pattern. Childs Nerv Syst. 21(8-9):628-34, 2005
  34. Srinivasan S et al: Features of the metabolic syndrome after childhood craniopharyngioma. J Clin Endocrinol Metab. 89(1):81-6, 2004
  35. Behari S et al: Intrinsic third ventricular craniopharyngiomas: report on six cases and a review of the literature. Surg Neurol. 60(3):245-52; discussion 252-3, 2003
  36. Saeki N et al: MR imaging study of edema-like change along the optic tract in patients with pituitary region tumors. AJNR Am J Neuroradiol. 24(3):336-42, 2003
  37. Barajas MA et al: Multimodal management of craniopharyngiomas: neuroendoscopy, microsurgery, and radiosurgery. J Neurosurg. 97(5 Suppl):607-9, 2002
  38. Fujimoto Y et al: Craniopharyngioma involving the infrasellar region: a case report and review of the literature. Pediatr Neurosurg. 37(4):210-6, 2002
  39. Green AL et al: Craniopharyngioma in a mother and daughter. Acta Neurochir (Wien). 144(4):403-4, 2002
  40. Sekine S et al: Craniopharyngiomas of adamantinomatous type harbor beta-catenin gene mutations. Am J Pathol. 161(6):1997-2001, 2002
  41. Van Effenterre R et al: Craniopharyngioma in adults and children: a study of 122 surgical cases. J Neurosurg. 97(1):3-11, 2002
  42. Chen CJ: Suprasellar and infrasellar craniopharyngioma with a persistent craniopharyngeal canal: case report and review of the literature. Neuroradiology. 43(9):760-2, 2001

Images

Selected Images

Sagittal graphic shows a predominantly cystic, partially solid, suprasellar mass with focal rim Ca⁺⁺. Note the small intrasellar component and fluid-fluid level. Craniopharyngiomas are the 90% tumors (90% cystic, 90% Ca⁺⁺, and 90% enhancing). Sagittal graphic shows a predominantly cystic, partially solid, suprasellar mass with focal rim Ca⁺⁺. Note the small intrasellar component and fluid-fluid level. Craniopharyngiomas are the 90% tumors (90% cystic, 90% Ca⁺⁺, and 90% enhancing).

Sagittal graphic shows a predominantly cystic, partially solid, suprasellar mass with focal rim Ca⁺⁺. Note the small intrasellar component and fluid-fluid level. Craniopharyngiomas are the 90% tumors (90% cystic, 90% Ca⁺⁺, and 90% enhancing). Sagittal graphic shows a predominantly cystic, partially solid, suprasellar mass with focal rim Ca⁺⁺. Note the small intrasellar component and fluid-fluid level. Craniopharyngiomas are the 90% tumors (90% cystic, 90% Ca⁺⁺, and 90% enhancing).

Sagittal T2 MR in a 9 year old with headache and visual changes shows a heterogeneous cystic and solid sellar and suprasellar craniopharyngioma  with anterior extension into the sphenoid sinus  and superior displacement of the optic chiasm. Sagittal T2 MR in a 9 year old with headache and visual changes shows a heterogeneous cystic and solid sellar and suprasellar craniopharyngioma with anterior extension into the sphenoid sinus and superior displacement of the optic chiasm.

Coronal T2 MR in a 48-year-old man who presented with visual changes shows a cystic suprasellar mass  with a focal T2-hypointense nodule  . The T2 imaging mimics a Rathke cleft cyst. Coronal T2 MR in a 48-year-old man who presented with visual changes shows a cystic suprasellar mass with a focal T2-hypointense nodule . The T2 imaging mimics a Rathke cleft cyst.

Sagittal T1 C+ MR in a 45-year-old woman shows a cystic and solid mass with an enhancing portion , which distinguishes this cystic lesion as a craniopharyngioma, not a Rathke cleft cyst. Surgical resection is the primary therapy for this WHO grade 1 neoplasm. However, the recurrence rate at 10 years approaches 20%. Sagittal T1 C+ MR in a 45-year-old woman shows a cystic and solid mass with an enhancing portion , which distinguishes this cystic lesion as a craniopharyngioma, not a Rathke cleft cyst. Surgical resection is the primary therapy for this WHO grade 1 neoplasm. However, the recurrence rate at 10 years approaches 20%.

Gross pathologic specimen shows a typical solid and cystic composition  of an adamantinomatous craniopharyngioma. The cystic spaces contain a thick gelatinous material. (Courtesy AFIP.) Gross pathologic specimen shows a typical solid and cystic composition of an adamantinomatous craniopharyngioma. The cystic spaces contain a thick gelatinous material. (Courtesy AFIP.)

Coronal T2 MR in a 2 year old with a huge suprasellar mass shows multiple hyperintense cysts . Adamantinomatous craniopharyngiomas typically present between 5-15 years in childhood and between 45-60 years in adults. They are the most common pediatric intracranial tumor of nonglial origin. Coronal T2 MR in a 2 year old with a huge suprasellar mass shows multiple hyperintense cysts . Adamantinomatous craniopharyngiomas typically present between 5-15 years in childhood and between 45-60 years in adults. They are the most common pediatric intracranial tumor of nonglial origin.

Axial NECT shows classic findings of an adamantinomatous craniopharyngioma. Note the large suprasellar cyst with a fluid-fluid level , rim , and globular   Ca⁺⁺. Enhancement was present on postcontrast images. Axial NECT shows classic findings of an adamantinomatous craniopharyngioma. Note the large suprasellar cyst with a fluid-fluid level , rim , and globular Ca⁺⁺. Enhancement was present on postcontrast images.

Sagittal gross pathology shows classic adamantinomatous craniopharyngioma with mixed solid, cystic components. The classic machine or "crankcase oil"  is present. Note the intrasellar extension . (Courtesy R. Hewlett, MD.) Sagittal gross pathology shows classic adamantinomatous craniopharyngioma with mixed solid, cystic components. The classic machine or "crankcase oil" is present. Note the intrasellar extension . (Courtesy R. Hewlett, MD.)

Sagittal T1 C+ MR in a 45-year-old man with visual changes shows a solid enhancing suprasellar mass . Papillary craniopharyngioma was diagnosed at resection. Papillary craniopharyngiomas are WHO grade 1 tumors; however, they are more commonly solid, noncalcified lesions. Sagittal T1 C+ MR in a 45-year-old man with visual changes shows a solid enhancing suprasellar mass . Papillary craniopharyngioma was diagnosed at resection. Papillary craniopharyngiomas are WHO grade 1 tumors; however, they are more commonly solid, noncalcified lesions.

Sagittal T1WI C+ MR shows a large recurrent craniopharyngioma in the central skull base and nasopharynx  with typical heterogeneous cystic and solid morphology. (Courtesy S. Blaser, MD.) Sagittal T1WI C+ MR shows a large recurrent craniopharyngioma in the central skull base and nasopharynx with typical heterogeneous cystic and solid morphology. (Courtesy S. Blaser, MD.)

Additional Images

Axial T1 C+ MR in a child with a huge multilobulated craniopharyngioma shows rim  and solid nodular  enhancement. Note that the cyst fluid is moderately hyperintense compared to CSF in the lateral ventricles. Axial T1 C+ MR in a child with a huge multilobulated craniopharyngioma shows rim and solid nodular enhancement. Note that the cyst fluid is moderately hyperintense compared to CSF in the lateral ventricles.

Axial DWI MR in the same patient with a large craniopharyngioma shows no restriction in the fluid-containing part of the tumor . Axial DWI MR in the same patient with a large craniopharyngioma shows no restriction in the fluid-containing part of the tumor .

Axial NECT shows a low-attenuation suprasellar mass with rim  and globular  Ca⁺⁺. Note the fluid-fluid level formed by intracystic keratin debris . Axial NECT shows a low-attenuation suprasellar mass with rim and globular Ca⁺⁺. Note the fluid-fluid level formed by intracystic keratin debris .

Sagittal T1WI MR shows a complex predominantly cystic suprasellar mass. Note the T1 shortening within the cyst due to machine oil-like proteinaceous fluid . Sagittal T1WI MR shows a complex predominantly cystic suprasellar mass. Note the T1 shortening within the cyst due to machine oil-like proteinaceous fluid .

Axial NECT shows a predominantly solid, minimally calcified  , suprasellar craniopharyngioma. Axial NECT shows a predominantly solid, minimally calcified , suprasellar craniopharyngioma.

Sagittal T1 C+ MR shows a principally cystic, sellar/suprasellar mass with rim enhancement . Sagittal T1 C+ MR shows a principally cystic, sellar/suprasellar mass with rim enhancement .

Sagittal T1 C+ MR in a 48-year-old man with visual changes shows an enhancing nodule , which distinguishes this cystic lesion as a craniopharyngioma, not a Rathke cleft cyst. Surgical resection is the primary therapy for this WHO grade 1 neoplasm; however, the recurrence rate at 10 years approaches 20%. Sagittal T1 C+ MR in a 48-year-old man with visual changes shows an enhancing nodule , which distinguishes this cystic lesion as a craniopharyngioma, not a Rathke cleft cyst. Surgical resection is the primary therapy for this WHO grade 1 neoplasm; however, the recurrence rate at 10 years approaches 20%.

Sagittal T1WI C+ MR shows a complex cystic suprasellar mass with an enhancing rim  and solid components . The cysts contain fluid of different signal intensities. Note the large suprasellar, smaller intrasellar  components in this classic craniopharyngioma. Sagittal T1WI C+ MR shows a complex cystic suprasellar mass with an enhancing rim and solid components . The cysts contain fluid of different signal intensities. Note the large suprasellar, smaller intrasellar components in this classic craniopharyngioma.

A short TE (35) H-MRS in a patient with a solid and cystic craniopharyngioma acquired from the center of the cystic portion of the mass shows large lipid-lactate peaks , characteristic of the cholesterol and lipid constituents found in cysts of craniopharyngiomas. A short TE (35) H-MRS in a patient with a solid and cystic craniopharyngioma acquired from the center of the cystic portion of the mass shows large lipid-lactate peaks , characteristic of the cholesterol and lipid constituents found in cysts of craniopharyngiomas.